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Senescence is a normal biological process that occurs in all organisms and involves a decline in cell functions.This process is caused
by molecular regulatory machinery alterations, and it is closely related to telomere erosion in chromosomes. In the context of the
immune system, this phenomenon is known as immunosenescence and refers to the immune function deregulation. Therefore,
functions of several cells involved in the innate and adaptive immune responses are severely compromised with age progression
(e.g., changes in lymphocyte subsets, decreased proliferative responses, chronic inflammatory states, etc.). These alterations make
elderly individuals prone to not only infectious diseases but also to malignancy and autoimmunity. This review will explore the
molecular aspects of processes related to cell aging, their importance in the context of the immune system, and their participation
in elderly SLE patients.
1. Introduction
Aging can be defined as the progressive decay of tissue func-
tions which eventually results in organ dysfunction and
death.This declinemay be the result of the loss of postmitotic
cell function or the lack of replacement of such cells due
to a decreased stem cell ability to maintain cell division
and replication [1]. If the organism suffers damage and it is
irreparable, the senescence or aging process will take place
by limiting the cells’ proliferative potential. Some control
mechanisms include differential gene expression which may
be detrimental [2]. However, there is a renewal mechanism
that ensures damaged cell replacement. This singular mecha-
nism corresponds to a set of proliferating precursor cells that
provide a source of cell replacement within the tissues. The
immune system provides an interesting case of replacement:
cells that die by apoptosis are replaced by new ones, a
process which is essential for immune system longevity and
for adequate functionality. This review will describe main
molecular mechanisms implicated in immunosenescence
and their relationship with autoimmune disease, particularly
related to systemic lupus erythematous (SLE).
2. Aging Molecular Mechanisms
One of the most striking features of cell aging is its close rela-
tionshipwith telomere length [3].There is an inverse relation-
ship between telomere length and cellular aging; for example,
very short telomeres force their cells to enter senescence.
Human telomeres contain guanine-rich repetitive sequences
(i.e., TTAGGG) which are gradually lost in each mitotic
division. This occurs by the fact that the DNA polymerase is
unable to replicate linear chromosomes in a process known as
telomere erosion (Figure 1) [4–6].This process functions as a
mitotic clock for which the length of the telomeres represents
the number of cell divisions sustained by the cells [7].
There is also a significant variability with respect to the
speed and quality of aging between and within populations
[8]. This heterogeneity results from interaction between
genetic, environmental, and stochastic factors. In this regard,
several epigenetic alterations have been associated with aging
and diseases caused by aging (e.g., DNA methylation state,
histone modification, miRNA, etc.) [9]. Several studies about
DNA methylation have shown loss of methylcytosines with
age, especially in CpG islands within Alu repetitive sequences
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Figure 1: Factors related to telomere erosion. The mechanisms
contributing to the loss of telomere length include genetic defects,
chronic viral infections, defects in repair machinery, aging, and
stress.
and endogenous retroviral sequences. On top of this, a study
of monozygotic twins showed that, for other young people,
they retain similarmethylation profileswhile other twinswho
were between 50 and 60 years old had different methylation
profiles and an H3 and H4 differential acetylation state [10].
Another mechanism related to epigenetic changes in
aging involves chromatin remodeling. This includes H3K9,
H3K27, and H4K20 trimethylation, decreased H3K9 acetyla-
tion, and increased H3S10 phosphorylation [11]. A decrease
in H3K27 methylation together with an augmentation in
H3S10 phosphorylation supports the idea of a change in the
heterochromatin and euchromatin dynamics in aging cells.
In addition, there are several chromatin remodeling-related
proteins that suffer alterations during aging.These include the
histone deacetylases (HDACs), the sirtuin 1 (SIRT1) protein,
and the histone methyltransferases [12].
Finally, several studies in both murine and humans have
shown that miRNAs may influence aging and longevity. Re-
cently, multiplemiRNAs related to aging have been described
including lin-4, miR-1, miR-145, miR-140, miR-34a, andmiR-
449th, and some of them modulate cell senescence critical
molecules such as class I HDAC, SIRT1, p21, p53, and
pRb. Another important miRNA related to TCR signaling
(miR181a) has serious implications in elderly people and
autoimmunity (this topic will be discussed later). Recently,
Liu et al. summarized themiRNAs involved in cell senescence
[13].
3. Immunosenescence
One characteristic of elderly people is their inability to
respond properly to vaccines and infections. This condition
could be the result of their low immune system efficiency
[14] and occurs because of thymic involution in which
the thymus loses its ability to produce and replace na¨ıve
T cells on the periphery. As a result, thymic dysfunction
produces a decrease in cell-mediated response to foreign
antigens, self-tolerance, and na¨ıve T-cell population. In
turn, it could increase the autoproliferation of T cells and
eventually the induction of premature T-cell maturation
which would also conduce to tolerance reduction [15]. These
alterations lead to not only modifications in lymphocyte
subsets but also to functional changes in cell population
subsets. For instance, longitudinal studies have demonstrated
an association between immunosenescence and an increase
in cytomegalovirus (CMV) anergic CD8 T cells [16].
One of the main characteristics of the immune system is
the constant renewal of its cells. At the same time, this renewal
is highly dependent on the efficiency of telomere mainte-
nance. Immune system cells are derived from hematopoietic
progenitor cells that come from myeloid and lymphoid lin-
eages. These cells are constantly dividing and differentiating
throughout their lifespan and that leads to changes in their
telomere length. Note that a high rate of telomere loss in the
first years of life has been observed, perhaps because of their
high rate of mitotic division. However, this telomere loss is
not a linear process over time since, in older people, it is
possible to find significant telomere erosion. In fact, several
studies have shown a decline in the length of telomeres with
aging [17]. A lot has been written regarding the relationship
between aging, thymic degeneration, and changes in the
bone marrow cells [18–20]. However, we will focus only on
immune senescence with an emphasis on circulating cell
populations.
There are reports about age-related changes in peripheral
blood cell populations: increase in monocytes, decreased
lymphocytes, decrease in naı¨ve cells, and increase in mem-
ory cells (Table 1) [21]. Curiously, memory T cells (CD4+-
CD45RO+ and CD8+-CD45RO+) increase with age and are
preferentially located in tissue, whereas there is a similar
proportion ofCD45RA+ andCD45RO+ subsets in peripheral
blood [22]. Unlike somatic cells, lymphocytes have a robust
capability to proliferate given their clonal expansion and
present an overexpression in the telomerase. This process
ensures no significant telomere shortening during each divi-
sion. Interestingly, T cells possess several special features
regarding their phenotype and their telomere length. T-cell
memory cells have shorter telomeres than na¨ıve T cells, and
CD28+ T cells have longer telomeres than CD28− T cells.
Immune aging or immunosenescence not only affects
adaptive response but also has implications in the innate
response (Table 1) [23]. It has been found that older individu-
als who exhibit a breakdown of their innate immune barriers
such as epithelial skin barriers, lungs, and gastrointestinal
tract could be vulnerable to a pathogen attack. Among the
cell types involved in innate response, there are neutrophils,
macrophages, and natural killer (NK) cells, which also suffer
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Table 1: Age-associated changes in immune cell populations and functions.
Cell type Characteristics References
Innate immunity
Neutrophils
↓ Phagocytic chemotaxis capability
↓ Superoxide anion production
↓ Ability to respond to soluble factors (GM-CSF) and bacteria (LPS and fMLP)
↓Molecule recruitment into lipid raft, apoptosis, and signal transduction
[23, 70, 87, 140]
Dendritic cells
↓ Cell number, antigen presentation, TLR-mediated signaling, IFN I/III production,
chemotaxis, and endocytosis
↓ Ability to stimulate lymphocytes in the ill elderly
↑ Function in the healthy elderly
[23, 102, 141]
Macrophages
↓ Phagocytic activity and chemotaxis
↑ Synthesis of proinflammatory cytokines (IL-6, IL-8, TNF-𝛼, and IL-1𝛽)
↓ Apoptosis, superoxide production, and signal transduction
↓ TLR expression and function
↑ PGE2 production
↓MCH class II production
[23, 87, 142]
NK cells
↑ CD56dimCD57+ population
↓ Function of cytotoxicity
↓ Secretion of IFN-𝛾 induced by Interleukin 2 (IL-2)
↓HLA-DR, IFN-𝛼, CD57, and CD95
↓ Cell proliferation
↑ Production of IL-1, IL-4, IL-6, IL-8, and TNF-𝛼
[72, 143, 144]
Adaptive immunity
Cellular response
Thymus Involution from age of 9 months, thymic remnant after 50 years [20, 145]
T Cells
Variable number (↓ proliferation to PHA, varying age, and health status)—HLA
B8/DR3 associated with high proliferative responses
↑ Proportion of memory cells (CD45RO+), especially tissue CD8+
↓ Proportion of naı¨ve cells (CD45RA+)
↓ Proliferative capacity
↓ Synthesis of IL-2 receptor and IL-2 in memory cells
↓ CD28+
↑ CD28− T cells—mainly CD8+ CD28− (characterized by oligoclonal expansion,
shortening of telomeres, potentially decreased proliferation, resistance to apoptosis,
and increased production of TNF-𝛼 and IL-6)
↓ CD4 T lymphocytes
Change fromTh1 response to Th2 response with ↓ cell-mediated responses directed
against intracellular bacteria (Th1 function) and relative preservation of humoral
response (Th2 function)
↓ Treg population (CD4+ CD25+) that plays a role in the manifestations of
autoimmunity
Impaired immunological synapse formation and signaling pathways (calcium
response and phosphorylations)
↓ CD4/CD8 rate
[14, 145–147]
Humoral response
B Cells
↓ Pre-B lymphocytes with peripheral B lymphocyte count unchanged
↑ CD5+ B cells (CD19+ CD5+ clones B) that produce low affinity antibodies without
cooperation of T cell
↓ Na¨ıve B cells
Accumulation of memory B cells with ↓ diversity and affinity of antibodies
Reaching primary humoral response (dependent T cell cooperation).
Conserved secondary humoral response
[14, 33, 50, 53, 145, 148]
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Table 1: Continued.
Cell type Characteristics References
Immunoglobulins
↑ Serum levels of IgA and IgG (IgG1, IgG2, and IgG4).
Monoclonal immunoglobulin production by CD19+ CD5+ clones.
Secretion of non-organ-specific self-antibodies (rheumatoid factor, antinuclear
antibodies, antiphospholipid antithyroglobulines, and parietal cells).
[51, 113]
Interleukins
↓ IL-2 production because of the following:
↓ cooperation of T cells with antibody producer B cells,
↑ production of IL-4, IL-6, IL-8, IL-10, and TNF-𝛼,
↓ production of IL-1 and IFN-𝛾.
[14, 106, 145]
functional alterations through aging (Table 1). Immunose-
nescence also affects the response to immunization.There are
several reports indicating low response to infectious agents in
elderly individuals [24, 25]. Latent proinflammatory status in
old subjects is due to involution of thymus with subsequent
alteration of function and balance of na¨ıve, effector, and
memory cells. This status combined with the presence of
common and cumulative viral infections in the elderly (such
as cytomegalovirus and Epstein-Barr virus) produces overall
responses, loss of ability to control infectious diseases, and
decreased response to vaccinations. The cytokine environ-
mental balance (i.e., decline in the INF𝛾 : IL-10 ratio) in
challenge condition (i.e., influenza or other viral infections)
could decline the CD8+ cytotoxic ability, thus conducing to
high IL-10 response to virus challenge. Therefore, vaccines
that arouse inflammatory cytokines would be expected to
enhance protection in elderly subjects.
3.1. Adaptive Immune Response
3.1.1. T Cells. T lymphocytes suffer alterations due to aging.
Most of the observed changes are attributed to alterations
during the initial activation step of the T-cell receptor (TCR).
There is evidence of alteration in the downstream signaling
of the TCR in the case of elderly people. This includes a
decrease in intracellular free calcium, deficiencies in protein
kinase C translocation, low Lck, ZAP70 activation, NFAT
impairment, NF-𝜅B translocation, low ras-mitogen activated
protein kinase (MAPK) pathways, and a decrease in protea-
some activity, [26].These alterations have been demonstrated
in both na¨ıve and memory T cells [27].
TCR has the function to discriminate between self-
antigens and respond to foreign peptides.This is caused by its
activation threshold level, and therefore, the loss of TCR sen-
sitivity is closely related to aging. As mentioned before, there
is an importantmicroRNA—namedmiR-181a—implicated in
this phenomenon which controls the expression of several
phosphatases related to the negative regulation of proximal
CD4 TCR signaling events. Indeed, in a murine model,
miR181a overexpression lowers TCR activation threshold and
restores TCR ability to respond to autoantigens [28]. Note
that miR-181a expression declines throughout life and shows
a significant loss after the age of 70 [29].
Another interesting point is that there are reports indi-
cating changes in gene expression of surface molecules on
T cells. Changes in surface molecules may have a negative
impact onT-cell activation by increasing phosphatase expres-
sion such as DUSP family. Furthermore, a study evaluated the
effect of aging on surfacemolecule gene expression and found
that IL-6R, CD8, CD27, and CD28 are downregulated while
ILT2 (CD85j), KLRG,KIR, CD44, CD96, Klrf1, andCD94 are
upregulated [30, 31]. Some of these molecules (ILT, KLRG,
and KIR) function as negative regulators of TCR activation
and proliferation (at least in murine models) or as specific
molecules of particular T cells such as cytomegalovirus
(CMV) peptide-specific T cells (KIR and ILT2). They also
appear to be related to T-cell exhaustion although the rela-
tionship between aging, senescent, and exhausted T-cell gene
expressions seems to be different (Figure 2). An excellent
review of this topic was done by Cavanagh et al. [32].
In addition to surface molecule gene expression alter-
ation, there are other processes related to TCR signaling
alteration and aging. For instance, it is well known that a
cell-intrinsic environment (ROS species, DNA damage) and
a cell-extrinsic environment (cytokines) both modulate TCR
responses, and they are also altered in the elderly. Moreover,
studies have shown that increased oxidative stress produces
displacement of LAT from the cell membrane, thus inhibiting
TCR signaling. Along with this, activated CD4 T cells from
aging humans express increased levels of metallothoineins,
which are an important redox system [34]. Additionally, there
are alterations in molecules that participate in nuclear and
cytoplasmic signaling pathways such as DNA repair kinases
(ATM, ATR, and DNA-PKCs), which are activated not only
by DNA double-strand breaks (DSB) but also by telomere
attrition (as we will see later). Both of them are related to
activation of DNA repair kinases (ATM, ATR and DNA-
PKcs) [35].
Host environment and specific cytokine profiles have
enormous implications in the T-cell signaling threshold.
Some cytokines such as IL-7, IL-21, and IL15 have been
studied in this regard. These cytokines signal through PI3K,
STAT3, and STAT5 [36] and participate in ERK pathway
activation. Note that IL-7 and IL-15 have profound impli-
cations in lymphopenia development in RA animal models.
This has been shown through the fact that when animals are
primed with IL-7 or IL-15, T-cell response to autoantigens
is enabled. In addition, another cytokine implicated in sig-
naling alteration during aging is the IL-6. This cytokine has
implications in the JAK-STAT pathway through activation of
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Figure 2: Changes in the T-cell pool and individual cells during aging. A Proportion of T subsets depends on individual infection antecedents
and the environment. Memory T-cell subset can change to senescence by a chronic latent infection and chronic TCR stimulation. Meanwhile,
exhausted T cells are produced by the same type of stimulation and the chronic acute infection. Aged na¨ıve cells are generated from na¨ıve
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Figure 3: Schematic representation of T-cell divisions and their
implication in telomere erosion and aging. Constantly dividing cells
are accompanied by a decrease in their telomere length, which is
related to aging phenotype: decreased Bim expression, increased
na¨ıve lifespan, and important functional changes.
SOCS3 transcription. Note that STAT molecules are highly
phosphorylated in elderly humans, a phenomenon that also
occurs through type I interferon T-cell activation [35].
As was discussed previously, telomere attrition is very
frequent in elderly people and it is also known that T-cell
replication is important for maintaining lymphocyte func-
tion. This suggests that T-cells employ the best mechanisms
for telomere maintenance during clonal expansion. Indeed,
there is evidence that telomerase activity is highly regulated
during T lymphocyte development and differentiation [37].
The resting CD4+ and CD8+ and naı¨ve T cells recorded no
telomerase activity on the periphery. However, the telom-
erase is activated by lymphocyte stimulation. The level of
telomerase activity decreases during successive stimulations
of the lymphocyte (Figure 3) [38]. The rate of telomere
shortening seems to be different among CD4+ and CD8+
cells, and it has been estimated to be 33 bp/year for CD4+
T cells and 26 bp/year for CD8+ T cells. One of the most
outstanding features of aged CD4+ na¨ıve T cells is their
inability to produce significant levels of IL-2 after stimulation
of their T-cell receptor (TCR). This inability subsequently
leads to poorTh1/Th2 polarization. However, these cells may
retain their ability to suffer Th17 differentiation [39, 40],
which, in turn, could favor an inflammatory and autoimmune
phenotype development. On the other hand, the number
of CD4+CD25+FOXP3+ regulatory T cells (Treg) increases
(2.4-fold), and they retain and gain functions during aging.
Nonetheless, their ability to produce IL-10 is low. They may
also contribute toTh17 bias (production of high levels of IL-17,
IL-21, and IL-22) and show a decrease in antitumor responses
too [40]. Meanwhile, aging CD8+ lymphocytes show a reduc-
tion in the diversity of the TCR repertoire, low antitumor
response, and marked clonal expansion development but
without the ability to replicate after stimulation [26]. Note
that Th2 inflammatory cytokines favor antibody production
by B cells, and this condition could explain autoantibodies in
the aged population.
One of the most important traits of immune aging is the
loss of theCD28 surfacemarker. CD28 is one of themolecules
expressed inT cells that provide costimulatory signals that are
required for T-cell activation, T-cell proliferation, cytokine
production, and T-cell survival promotion. Loss of CD28
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expression is a phenotypic change associated with senescence
in T lymphocytes, and it has been associated with func-
tional alterations such as enhanced cytotoxicity, suppressive
functions, and resistance of CD4+ T cells to apoptosis. Loss
of CD28 expression is characterized by telomere shortening
and reduced proliferative ability, both ex vivo and in vitro
[41, 42]. At birth, virtually all T cells express CD28, but
with age, the marker decreases about 40 to 50% for CD8+
T cells and 85 to 90% for CD4+. This reduction in the
markers is attributed to repeated antigenic stimulation in
peripheral blood [43]. However, when the CD28 is lost, cells
suffer reprograming and, as a consequence, they express
new receptors such as KIR, CD70, and perforin. Moreover,
phenotypic CD28− T-cell characteristics include interferon
gamma (IFN-𝛾) production, potent cytotoxic capability, and
CD158, CD158b, CD158J, DAP12, CD94, and CD244 receptor
expression (similar to NK cell characteristics). These recep-
tors give them the potential to interact with accessory cells
such as mesenchymal cells, which include the fibroblasts of
inflamed joints [44]. Furthermore, in elderly individuals with
chronic viral infections and autoimmune diseases (e.g., mul-
tiple sclerosis (MS), rheumatoid arthritis (RA), andWegener’s
disease), an increase in the frequency of CD28− T cells has
been detected [43]. It has been suggested that autoantigens
can lead to clonal expansion of these cells. Thus, there are
reports [45, 46] indicating how they can, for instance, show
reactivity to myelin basic protein (MBP). The presence of
CD4+ CD28− T cells in both elderly individuals and patients
with autoimmune diseases (ADs) has supported the concept
that ADs are closely related to the cell aging process. In
this regard, the loss of CD28 molecule could favor CTLA-4
interaction with their ligands (CD80 and CD86), which are
implicated in autoimmune phenotype too.
The main differential and functional alterations of CD4+
and CD8+ T-cell subsets are summarized in Figure 4.
3.1.2. B Cells. It is known that with aging, there is a decrease
in not only the frequency and absolute number of pro-
B cells but also in their ability to differentiate into pre-B
(between 60 and 90%). Nevertheless, in healthy individuals,
mature peripheral B-cell numbers do not change with aging;
instead the relationship between na¨ıve and memory cells is
altered; that is, there is an increase in long-livedmemory cells
(homeostatic expansion of antigen-experienced or activated
B cells) and a decrease in na¨ıve cells [47]. This condition
seems to depend on different factors other than genetic ones.
A study comparing old individuals with healthy centenarian
offspring could determine that centenarian offspring have
more IgD+ CD27− na¨ıve B cells than older people. Neverthe-
less, the double negative memory cells (IgD− CD27− B cells)
are only found in healthy elderly individuals, and there are
no differences between groups [48]. Recently, studies have
reported a novel peripheral B-cell subset in the elderly named
aging-associatedB-cell (ABC) subset (CD19+CD11b+CD11c+)
[49]. In vitro, the ABC subset responds only to innate stimuli
producing secretion of autoantibodies and cytokines, and this
subset also has the ability to potentiateTh17 polarization, thus
relating it to an autoimmune phenotype.
Another important fact is the presence of alterations in
the repertoire of the B-cell receptor (BCR), which exhibits
a decreased affinity and diversity to the antibody response
with aging [33]. Indeed, elderly patients have impaired B-
cell proliferation and activation, possibly as a result of
defects in their threshold of activation [26]. Also, there is
a loss of precision in distinguishing self- from non-self-
antigens due to the oligoclonal expansion of the B lymphocyte
subpopulationwith a high proportion of antigen-experienced
cells [50].This subpopulation expresses CD5 on their surface,
thus giving them the ability to produce low affinity antibodies
independently of T cells. In the context of autoantibody
generation, this is important for triggering an autoimmune
response.
Moreover, the germinal centers (GC) from elderly peo-
ple are small and have few cells producing IgM. In these
individuals, levels of immunoglobulins, especially IgA and
IgG, are increased [51]. Furthermore, it has been shown that
IgG+/IgA+ B-cell subsets (both CD27+ and CD27−) express
Ig mutated genes in their variable regions and high levels of
CD80 and CD86 on their surface, thus exhibiting a similar
B-cell memory phenotype [52]. According to the reports,
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Figure 5: Age-related changes in the generation and function of B cells. There is a reduced output of B cells in the bone marrow, which
induces accumulations in the periphery of antigen-experienced subsets with poor immune response and low diversity. HSC: hematopoietic
stem cell; BCR: B-cell receptor; BM: bone marrow (adapted from [33]).
this subtype of cells declines with aging [51]. Finally, aging
B cells have been observed to produce antibodies with low
avidity because of their somatic hypermutation deterioration
which leads to a gradual decline in the humoral response.
Nevertheless, repertory changes are not synchronous with
aging, and decreased diversity has been related to poor health
status [53].
An interesting study [54] done to evaluate na¨ıve
(CD19+CD27−) and memory (CD19+CD27+) switch B-cell
subsets in elderly individuals showed a decrease in total B
cells, and, although the quantity of na¨ıve cells increased in
percentage, they decreased or remained constant in number.
Moreover, another striking result is that the B-cell memory
(CD27+) increased in percentage but not significantly. In
contrast, memory cells producing IgM subtype decreased in
number but not in percentage. Finally, the memory switch
cells decreased both in number and percentage with aging.
An interesting point about memory B cells is that they have a
hyporesponsive state to antigen-induced activation with less
clonal expansion or less ability to differentiate into antibody
secreting cells [55]. This condition may be caused by the
decreasing number of antibody high affinity B cells that
elderly people have.
Taken together, these results indicate that there is an
accumulation of antigen-experienced B subsets in aging indi-
viduals. In these cases, overall B-cell numbers are unchanged,
but they vary in their functional abilities (Figure 5).
3.2. Innate Immune Response
3.2.1. Dendritic Cells. Dendritic cells (DCs) are important
because they function as a checkpoint between immunity and
tolerance. DCs from aging individuals display a basal level of
activation, increased secretion of proinflammatory cytokines
such as TNF-𝛼 and IL-6 [56], and high levels of NF-𝜅B acti-
vation. However, they do not exhibit upregulation of CD86
and CD80 molecules on their surface, which suggests that
they are partially activated. Another important characteristic
is that they are more reactive to self-antigens compared with
their young counterparts and display an impaired clearance
of apoptotic cells and antigens [57]. This could produce a
higher presentation of self-antigens and, consequently, an
activation of autoreactive lymphocytes. An interesting point
is that these partially activated DCs have a greater ability to
stimulate T cells, thus indicating that their ability to induce
tolerance to self-antigens is affected.
Some explanations have been given regarding partially
activated DCs: (1) an increased age-associated level of proin-
flammatory mediators and (2) age-associated modifications
in autoantigens, which increase their immunogenicity [58].
Note that the functions of myeloid DCs (mDCs) such
as IL-12 production, chemotaxis, and their ability to activate
na¨ıve CD4 T cells via antigen presentation appear to be
altered in elderly individuals [57]. This inability is due to
decreased PI3K activation [59], which leads to activation of
NF-𝜅B, as it was previously mentioned. This subtype of DCs
also shows decreased capability in their antigen processing
and increased expression of CD86.
Plasmacytoid DCs (pDCs) from elderly people, in turn,
have reduced IFN I and IFN III production after stimulation
via Toll-like receptor (TLR) [60]. Additionally, they have an
impaired ability for antigen presentation to CD4 and CD8 T
cells.
3.2.2. Neutrophils. Neutrophils are the first immune cells that
are recruited to the site of infection or to the tissue damage
[61]. Besides, there is a debate about whether the numbers of
neutrophils change with age, but a variety of studies suggest
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that there are no number changes. However, there are reports
indicating several functional defects in neutrophils from the
elderly [62, 63]. The main function decreased in neutrophils
is the chemotaxis, followed by the phagocytic activity. Both
of them affect the time needed for the neutrophils to reach
the infection site and their ability to control the infections,
respectively [62, 64, 65]. These two alterations are closely
related to increased infections in elderly subjects.
Low phagocytic activity has been associated with reduced
surface expression of the Fc𝛾 receptor CD16 [64]. Signaling
function of other receptors involved in activation such as
fMLp, TLR, retinoic-acid-inducible-gene-1-protein- (RIG-
1-) like helicases (RLRs), nucleotide binding domain and
leucine-rich-repeat-containing proteins (NLRs), and C3b has
been reported to be significantly altered.This alteration is due
to changes in signaling molecules but not in the number of
their receptors [66, 67]. Some downstream signaling events
include phosphoinositide-3 kinase (PI-3 K), MAP kinase,
Calcium, protein kinase B, and SHP-1 and Jak-STATpathways
[68]. Interestingly, these alterations are produced by changes
in membrane composition including lipid rafts distribution
and their structure [69, 70].
3.2.3. NK and NKT Cells. NK cells participate in the innate
immune defense against intracellular pathogens and tumor
cells, and theymediateMHC-independent cytotoxicity.There
are several studies indicating a remodeling of these cells
in elderly individuals. The percentage and absolute number
of NK cells are increased in healthy aging, and they are
characterized by the increment of CD57 expression and
expansion of CD56dim NK cells (mature and highly differ-
entiated cells) [71, 72]. Other important features of these cells
from aging subjects are decreased proliferative response to
cytokines, altered expression of some NK receptors such as
natural cytotoxicity receptors (NCRs) [73], CD226 [74], and
KLRG-1 [75], and increased expression of HLA-specific killer
immunoglobulin-like receptor [73].
At functional level, cytotoxic and proliferation ability and
cytokines/chemokines (such as INF𝛾, RANTES, MIP1a, and
IL8) production of NK cells are reduced [76].
NKT cells are important in the clearance of bacterial and
viral infections as well as in regulation of immune tolerance
and autoimmunity [77]. NKT cells are characterized by
expression of a TCR encoded by V𝛼14/V𝛽8.2 gene segments.
The effects of aging on NKT cell number and function
have been little studied. In general, nowadays, it is accepted
that the absolute number of NKTs within the lymphoid organ
increases [78]. In addition, there are reports that show a
decrease of proliferative ability and low number of CD1d-
restricted NKT cells in the peripheral blood [79]. Studies
of inhibition of NKT cell activation demonstrated age-
associated decay of proliferative response and retarded type
hypersensitivity responses [80]; in addition, results showed
that NKT cells contribute to increments of IL-4 and IL-10
production and decreased IFN-𝛾 in aging subjects [81].
3.2.4. Monocyte/Macrophages. Other essential components
of innate immune response are macrophages andmonocytes.
Monocytes respond to inflammation by their differentiation
into macrophages and dendritic cells. Studies have demon-
strated that CD56+ monocytes subpopulation (high produc-
ers of TNF-𝛼 via TLRs 2 and 4) is increased with age while
their counterpart (CD56−) is decreased [82]. The increment
of CD56+ monocytes is paradoxical with the alteration in
macrophage TLR function. A study revealed a decrease in
IL-6 and TNF-𝛼 via TLR1/2 in the elderly, and this fact was
related to the decrease of TLR1 on monocyte surface [83].
These results are contradictory with another report which
indicates substantial increase of the same cytokines [21].
Thus, this issue required further confirmation, which can
be accomplished by the study of phenotype subpopulations
(according to the expression levels of the receptors and
proteins). In this regard, age-associated changes in TLRs
expression on monocytes have been performed [84]. A
particular study showed that old patients infected with West
Nile virus have a persistent TLR3 expression onmacrophages’
surface while young patients have reduced expression of this
receptor [85]. This feature may produce a higher inflamma-
tory response with the subsequent increased morbidity of
elderly subjects.
Furthermore, there are reports about age-related upregu-
lation of CD80 molecule on monocytes after TLR activation
[86] which is associated with production of a protective
response to influenza vaccination.
Another important age-associated feature of both mono-
cytes and macrophages is that several of their receptors
become altered, thus producing cells dysfunction. This pro-
duces that clearance of free radical production and phago-
cytosis are reduced in monocyte/macrophages in the elderly
[87]. Also, these alterations may lead to deregulation in
clearing of apoptotic cells by macrophages, thus precipitating
the exacerbation of inflammatory-aging condition.
4. Infection and Immunosenescence
To produce an adequate response to large numbers of
pathogens throughout life, there are homeostatic mecha-
nisms guaranteeing competent memory and a naı¨ve cell
pool for prolonging the survival of memory cells. However,
under the conditions of advanced age, these mechanisms
are seriously affected. As we have seen, during aging, many
changes occur in the immune system, which means that
immunosenescence becomes a factor contributing signifi-
cantly to a higher risk and severity of infections. The most
important diseases in the elderly are urinary tract infections,
influenza andpneumonia, chronic viral infection reactivation
(herpes virus and varicella-zoster virus), as well as bacterial
(tuberculosis), fungal (candidiasis), or parasitic infections,
and,more rarely, opportunistic infections such asClostridium
and Staphylococcus [88, 89]. Although the immune response
to antigens may be preserved in elderly individuals, their
ability to be immunized against new antigens is reduced.This
may be the result of an increase in the proportion of memory
cells and progressive decrease in naı¨ve cells from the thymus
[90].
While it is true that aging is associatedwith the emergence
of infectious diseases, it is also true that these infectious
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events will promote aging. It is well known that viral
infections (particularly the herpes virus family) are strong
stressors which alter the lymphocyte phenotype and func-
tionality, altered cytokine profile, resistance to apoptosis,
and shortened telomeres [91]. These features are similar to
those found in the elderly; thus it is possible that viral
infections could represent an important extrinsic factor for
aging by the repeated antigen stimulation characteristic of
persistent latent infections [92]. Furthermore, it has been
suggested that latent herpes virus infections are primarily
responsible for in vivo generation of senescent CD8+ T cells,
perhaps due to constant and prolonged virus-specific T-cell
proliferation [93]. Additionally, the Epstein-Barr virus (EBV)
latent infection has also been associated with telomere short-
ening in antigen-specific CD8− T cells because EBV antigens
cause a decrease in telomerase activity associated with T-
cell proliferation [94]. In contrast (and related to telomere
erosion and its relationship with CD28molecule expression),
the majority of T cells in a study done by Vescocini were
CD28+ unlike what was found for CMV, which were mainly
CD28− [95]. During human immunodeficiency virus (HIV)
infection, in turn, it has been reported that early presence
of CD8+ CD28− T cells is a predictive characteristic of rapid
disease progression [96].
These data indicate that chronic infections during aging
produce significant changes in the CD8+ cell subset. Addi-
tionally, this shows that expansion of CD28− T cells is age
dependent, and they have a positive correlation with proin-
flammatory cytokines. At the same time, these cytokines
are heavily involved in the pathogenesis of immunological
disorders which could favor the emergence of different
pathologies including ADs.
5. Autoimmune Disease
Currently, it is clear that changes occurring in the immune
system during aging affect the onset of ADs. This is due to
the fact that aging is related to increased reactivity to self-
antigens and loss of tolerance. The overall tendency supports
this hypothesis because elderly people experience general
systemic inflammation and, at the same time, they aggravate
degenerative diseases [97], which, in turn, increase the risk of
developing ADs [98, 99]. Proinflammatory cytokines on gen-
eral systemic inflammation (produced by viral infection) lead
to a state called inflammaging, which corresponds to the loss
of equilibrium between adequate inflammatory response and
efficient anti-inflammatory control in the elderly condition.
Later, in normal aging, this control fails to fully neutralize the
inflammatory processes.
In addition to this, it is important to remember (as we
have seen previously) the epigenetic changes occurring in
elderly people and how these may affect important genes
involved in autoimmune disorder development [100]. In this
regard, there are reports in which some genes associated with
ADs are hypermethylated but others are hypomethylated.
For instance, FoxP3, a hypermethylated gene, is a member
of the forkhead transcription regulator family [101] and
is associated with the development of multiple ADs. In
contrast, the gene coding for the CD11a chain of lymphocyte
function-associated antigen 1 (LFA-1)—a protein which is
associated with certain ADs—is hypomethylated with age
and thus overexpressed in aging cells [100]. Furthermore,
there are other reports on elderly subjects indicating DNA
hypomethylation states which could lead to an increase in the
immunogenicity [58]
Another important aspect of aging that is closely related
to autoimmunity in general and ADs in particular is the
increase in inflammatory cytokines and chemokines such
as TNF-𝛼, C-reactive protein, IL-8, MCP1, and RANTES
[102–104]. There is a substantial amount of evidence of age-
associated alterations in the T-cell cytokine profile which
could contribute to development of ADs. Studies have shown
that there is a change from Th1 to Th2 molecules (mainly
IL-4 and IL-6) in the cytokine profile as age advances [105].
IL-6 is a potent proinflammatory cytokine closely related to
disability in patients with RA; therefore, IL-6 represents a
therapeutic target for this disease [106]. In addition, there
are reports of an imbalance between Th17 and Treg cells. A
considerable number of IL-17-secreting naı¨ve CD4+ T helper
cells have been detected in the elderly in contrast to reduced
IL-17-secreting memory CD4+ T helper cells [107].
Some ADs are very frequent in younger patients and
are not limited to elderly people although the occurrence or
presence of autoantibodies is greater at advanced age [108–
111]. Autoantibody production such as rheumatoid factor, as
well as antinuclear, antiphospholipid, and antithyroglobulin
antibodies, is present during aging [109, 112]. Autoanti-
body production has been attributed to altered T- and B-
cell functions [113], especially to the decrease in antibody
affinity maturation. This evidence supports the idea that
autoantibody levels may be closely related to the clinical
characteristics of the elderly and to patients with ADs.
One of the important causes of dysfunctional immune
responses is telomere abnormalities which may lead to
autoimmunity.This observation is significant since numerous
studies have shown an association between mean telomere
length in peripheral blood mononuclear cells (PBMCs) and
different diseases [91]. This evidence suggests an increase in
CD8+ CD28− T-cell proportions in several pathologies such
as in the case of some ADs.
Moreover, there are reports of telomere length alteration
in patients with ADs such as RA [114, 115], scleroderma (SSc)
[116], systemic lupus erythematosus (SLE) [117], polyangiitis
with granulomatosis [118], psoriasis, and atopic dermatitis
[119], suggesting an excessive cell replication with their
corresponding telomere erosion. These findings have been
interpreted as evidence of T-cell accelerated proliferation in
the autoimmune process.
At present, it is believed that there are differences among
telomere abnormalities and various ADs. Some of these
differences could be explained by the genetic background
of the individuals studied. For example, a study performed
in patients with SSc and their family members reported
short telomeres [116]. The idea of a genetic predisposition to
telomere shortening is also suggested in patients with RA,
who exhibit telomere erosion in not only memory cells but
also in na¨ıve cells.Moreover, this evidence shows acceleration
in telomere erosion occurring at the precursor cell level [120].
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Lupus in older adults
Associated with
Sjo¨gren’s syndrome
F/M sex ratio
from 2.5 to 9
Frequency of 3–18%
compared to all SLE
cases
↑ RF and antinucelar
antibodies
Milder disease course
Ocurrence of serositis
and pulmonary
involvement
Figure 6: General characteristics of late-onset SLE.There are different manifestations of older SLE patients compared to young patients. RF:
rheumatoid factor; F/M: female/male.
Another striking fact is that the genetic predisposition to
short telomeres is strongly related to HLA-DR4 haplotype
which is shared by RA and T1D in some individuals [121, 122].
5.1. Late-Onset Systemic Lupus Erythematous. Although SLE
is considered a disease of the reproductive stage of women,
there is evidence that it occurs between 3 and 18% in
individuals older than 50 years [123]. Despite that there are
aged SLE patients, their clinical manifestations, response to
treatment, prognosis, and course of the disease are different
in these individuals (Figure 6). For example, clinical man-
ifestations such as malar rash, renal disease, arthritis, and
photosensitivity are less frequent in them, while serositis,
cytopenias, and pulmonary involvement are more frequent
[124–127]. In addition, it has been shown that female/male
(F/M) sex ratio declines with age. Studies report F/M ratio
from 2.5 to 9 in elderly individuals compared to from 9.1 to
14.4 in young people [126, 128].
A striking feature of these patients is the differential
diagnosis due to the SLE overlapping with other diseases.
Late-onset rheumatoid arthritis, endocarditis, tuberculosis,
neoplasia, polymyalgia rheumatica, temporal arteritis, and
Sjo¨gren’s Syndrome (SS) had been described is these patients
[124, 127]. In the particular case of SS, elderly patients with
SLE and without SS have low frequency of compromising
renal disease, lymphadenopathy, and thrombocytopenia and
high frequency of Raynaud’s phenomenon [129].
Besides changes in clinical and serological profiles, sero-
logical profiles of aged SLE patients also exhibit alterations
[124]. Compared to younger individuals, elderly patients
with SLE have high frequency of rheumatoid factor (33%
versus 20%) and antinuclear antibodies but low frequency of
antiribonucleoprotein (anti-RNP, 10% versus 21%) and anti-
Sm (9% versus 17%). There are reports that indicate contra-
dictory results [130], but these differences can be explained
by different reasons: ethnicity, sample size, methodology, and
so forth.
An important fact is that the severity of the disease
appears to decrease with age. It has been reported that
late-onset SLE patients have milder disease course which is
reflected in a small number of relapses per patient. Addition-
ally, it was found that the prevalence of lupus nephritis and
nephrotic syndrome also is lower in elderly patients.
Currently, it is not clear if there is a relationship between
telomere loss and SLE. Some studies have shown an increased
telomere erosion in SLE patients [100, 101, 131, 132], while
others report normal telomere length when compared with
healthy controls [102, 103]. Nevertheless, it is clear that
there is a reduction in telomerase activity in na¨ıve CD4+ T
cells and an increased activity in B cells [101, 103]. In this
regard, a recent study showed a differential expression of
shelterin complexmolecules in patients with lupus [104], but,
unfortunately, it was not done cell specific.
According to the report of [132], shorter telomeres are
associated with Ro antibodies while longer ones with steroid
therapy and increased body mass index. However this study
also showed that short telomeres are not related to disease
activity or immune cell turnover, but they could be good
predictors of premature aging.
Related to this topic, previous studies have indicated that
bone marrow mesenchymal stem cells (BMSCs) from SLE
patients exhibit not only increased apoptosis and senescence
but also impaired capacity of differentiation, immune mod-
ulation, proliferation, and secretion of cytokines. Apoptosis
and senescence in BMSCs fromSLE patients appear, to be due
to increased favorable conditions for these processes. There
were described increased levels of p16INK4A, Bax, caspase 8,
Fas and tumor necrosis factor-a receptor 1, and the respective
ligands of the two last.There is also a decreased expression of
Bcl-2, CDK4, CDK6, and p-Rb [133, 134].
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Programmed cell death (PCD) is an essential mechanism
of homeostasis and development and it is very important
as an immune response regulator. Hence appropriate clear-
ance of apoptotic cells in the immune system is necessary
for regulating inflammation and maintaining self-tolerance.
Impaired clearance of apoptotic cells in patients with SLE
is considered an important process in the etiology of lupus
[135]. This phenomenon is exacerbated in older age, and its
deficiencies may account for the development of autoimmu-
nity by the loss of tolerance in lymphoid tissues. This process
is mediated by phagocytes and, as it was mentioned before,
in elderly subjects; phagocytic functions of macrophages are
altered. This functional deregulation may generate danger
signals, followed by concomitant exposure of autoantigens
and the subsequent autoimmune reaction.
Another mechanism that is related to development of
lupus is themolecularmimicry inwhichB andT cells are acti-
vated as a result of an infection. This mechanism makes cells
able to recognize self-molecules that are similar to infectious
agent molecules, thus originating an autoimmune response
[136–139]. In SLE, this response is associated with high levels
of anti-Sm autoantibodies due to similar molecular sequence
of pathogenicmolecules of CMV and EBV, which develop the
initial immune response. Although anti-Sm autoantibodies
are less frequent in the elderly than in younger individuals,
it may be possible that EBV infection—exacerbated with
age—can contribute not only to inflammaging development
but also to induction, by molecular mimicry, of an immune
response towards itself. Further studies in this topic could be
interesting.
Abnormalities in TCR signaling which have been docu-
mented in SLE patients are similar to those in RA patients.
This may also be related to the elderly; for instance, TCR zeta
chain expression is defective in these patients [105].
6. Concluding Remarks
Aging is a natural physiological process that could eventually
conduce to increases in some pathological conditions. A lot
of changes are detected in the immune system of elderly
individuals which could contribute to the occurrence of
complications such as infection, autoimmunity, and autoim-
mune disorders. In this regard, it is important to remember
that elderly patients with SLE have different clinical and
serological manifestations and poorer prognosis comparing
with young patients (less insidious onset disease, more
occurrences of severe manifestations, and higher frequency
of comorbid conditions). Thus it is necessary to implement a
proper immunological recognition of these patients in order
to produce adequate therapeutic management whichmust be
different because the treatment itself may cause long-term
damage.
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